Competition between tumor and mononuclear phagocyte system causing the low tumor distribution of nanoparticles and strategies to improve tumor accumulation

Current Drug Delivery

Volumn 13, Issue 8, 2016, Pages 1261-1274

  Yang, Bin ^b   Han, Xiaopeng ^c   Ji, Bin ^b   Lu, Rong ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^c CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Bio distribution; Liver; Mononuclear phagocyte system; Nanoparticles; Spleen; Tumor accumulation

Indexed keywords

LIGAND; MACROGOL; NANOPARTICLE; ANTINEOPLASTIC AGENT;

CANCER THERAPY; CAPILLARY; DRUG DELIVERY SYSTEM; LIVER; MONONUCLEAR PHAGOCYTE; NANOMEDICINE; NANOPHARMACEUTICS; PARTICLE SIZE; PRIORITY JOURNAL; REVIEW; SPLEEN; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIAL CELL; CHEMISTRY; HUMAN; METABOLISM; NEOPLASM; TISSUE DISTRIBUTION;

ANTINEOPLASTIC AGENTS; HUMANS; MONONUCLEAR PHAGOCYTE SYSTEM; NANOMEDICINE; NANOPARTICLES; NEOPLASMS; TISSUE DISTRIBUTION;

EID: 84995876947     PISSN: 15672018     EISSN: 18755704     Source Type: Journal    
DOI: 10.2174/1567201813666160418105703     Document Type: Review

References (137)

1. World Health Organization. World Cancer Report 2014. Effective prevention measures urgently needed to prevent cancer crisis. http://www.who.int./cancer/about/facts/en/index.html (Accessed Feb 06, 2014)
2. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: the next generation. Cell, 2011, 144, 646-674
3. Dawidczyk, C.M.; Kim, C.; Park, J.H.; Russell, L.M.; Lee, K.H.; Pomper, M.G.; Searson, P.C. State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines. J. Control Release, 2014, 187, 133-144
4. Min, Y.; Caster, J.M.; Eblan, M.J.; Wang, A.Z. Clinical Translation of Nanomedicine. Chem. Rev., 2015, 115, 11147-11190
5. Rose, P.G. Pegylated liposomal doxorubicin: Optimizing the dosing schedule in ovarian cancer. Oncologist, 2005, 10, 205-214
6. Kozak, D.; Broom, M.; Vogel, R. High Resolution Particle Characterization to Expedite Development and Regulatory Acceptance of Nanomedicines. Curr. Drug Deliv., 2015, 12, 115-120
7. Gill, P.S.; Wernz, J.; Scadden, D.T.; Cohen, P.; Mukwaya, G.M.; von Roenn, J.H.; Jacobs, M.; Kempin, S.; Silverberg, I.; Gonzales, G.; Rarick, M.U.; Myers, A.M.; Shepherd, F.; Sawka, C.; Pike, M.C.; Ross, M. E. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi’s sarcoma. J. Clin. Oncol., 1996, 14, 2353-2364
8. Miele, E.; Spinelli, G.P.; Miele, E.; Tomao, F.; Tomao, S. Albumin-bound formulation of paclitaxel (Abraxane (R) ABI-007) in the treatment of breast cancer. Int. J. Nanomed., 2009, 4, 99-105
9. Baluk, P.; Hashizume, H.; McDonald, D.M. Cellular abnormalities of blood vessels as targets in cancer. Curr. Opin. Genet. Dev., 2005, 15, 102-111
10. Deryugina, E.I.; Quigley, J.P. Tumor angiogenesis: MMP-mediated induction of intravasationand metastasis-sustaining neovasculature. Matrix Biol., 2015, 44-46, 94-112
11. Hashizume, H.; Baluk, P.; Morikawa, S.; McLean, J.W.; Thurston, G.; Roberge, S.; Jain, R.K.; McDonald, D.M. Openings between defective endothelial cells explain tumor vessel leakiness. Am. J. Pathol., 2000, 156, 1363-1380
12. Matsumura, Y.; Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res., 1986, 46, 6387-6392
13. Han, H.D.; Mangala, L.S.; Lee, J.W.; Shahzad, M.M.; Kim, H.S.; Shen, D.; Nam, E.J.; Mora, E.M.; Stone, R.L.; Lu, C.; Lee, S.J.; Roh, J.W.; Nick, A.M.; Lopez-Berestein, G.; Sood, A. K. Targeted gene silencing using RGD-labeled chitosan nanoparticles. Clin. Cancer Res., 2010, 16, 3910-3922
14. Sunoqrot, S.; Bugno, J.; Lantvit, D.; Burdette, J.E.; Hong, S. Prolonged blood circulation and enhanced tumor accumulation of folate-targeted dendrimer-polymer hybrid nanoparticles. J. Control. Release, 2014, 191, 115-122
15. Derycke, A.S.; Kamuhabwa, A.; Gijsens, A.; Roskams, T.; De Vos, D.; Kasran, A.; Huwyler, J.; Missiaen, L.; de Witte, P.A. Transferrin-conjugated liposome targeting of photosensitizer AlPcS4 to rat bladder carcinoma cells. J. Natl. Cancer Inst., 2004, 96, 1620-1630
16. Teesalu, T.; Sugahara, K.N.; Kotamraju, V.R.; Ruoslahti, E. C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. Proc. Natl. Acad. Sci. U.S.A, 2009, 106, 16157-16162
17. Tang, M.K.; Wong, A.S. Exosomes: Emerging biomarkers and targets for ovarian cancer. Cancer Lett., 2015, 367, 26-33
18. Yoo, J.W.; Chambers, E.; Mitragotri, S. Factors that Control the Circulation Time of Nanoparticles in Blood: Challenges, Solutions and Future Prospects. Curr. Pharm. Des., 2010, 16, 2298-2307
19. Li, Y.; Wang, J.; Wientjes, M.G.; Au, J.L. Delivery of nanomedicines to extracellular and intracellular compartments of a solid tumor. Adv. Drug Deliv. Rev., 2012, 64, 29-39
20. Dobrovolskaia, M.A.; Aggarwal, P.; Hall, J.B.; McNeil, S.E. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol. Pharm., 2008, 5, 487-495
21. Owens, D.E. 3rd; Peppas, N.A. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm., 2006, 307, 93-102
22. Aggarwal, P.; Hall, J.B.; McLeland, C.B.; Dobrovolskaia, M.A.; McNeil, S.E. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv. Drug Deliv. Rev., 2009, 61, 428-437
23. Nagayama, S.; Ogawara, K.; Fukuoka, Y.; Higaki, K.; Kimura, T. Time-dependent changes in opsonin amount associated on nanoparticles alter their hepatic uptake characteristics. Int. J. Pharm., 2007, 342, 215-221
24. Mackay, I.R. Hepatoimmunology: A perspective. Immunol. Cell Biol., 2002, 80, 36-44
25. Braet, F.; De Zanger, R.; Baekeland, M.; Crabbe, E.; Van Der Smissen, P.; Wisse, E. Structure and dynamics of the fenestraeassociated cytoskeleton of rat liver sinusoidal endothelial cells. Hepatology (Baltimore, Md.), 1995, 21, 180-189
26. Lee, H.A.; Leavens, T.L.; Mason, S.E.; Monteiro-Riviere, N.A.; Riviere, J.E. Comparison of Quantum Dot Biodistribution with a Blood-Flow-Limited Physiologically Based Pharmacokinetic Model. Nano Lett., 2009, 9, 794-799
27. Li, S.D.; Huang, L. Pharmacokinetics and Biodistribution of Nanoparticles. Mol. Pharm., 2008, 5, 496-504
28. Bertrand, N.; Leroux, J.C. The journey of a drug-carrier in the body: an anatomo-physiological perspective. J. Control Release, 2012, 161, 152-163
29. Cesta, M.F. Normal structure, function, and histology of the spleen. Toxicol. Pathol., 2006, 34, 455-465
30. Vonarbourg, A.; Passirani, C.; Saulnier, P.; Benoit, J.P. Parameters influencing the stealthiness of colloidal drug delivery systems. Biomaterials, 2006, 27, 4356-4373
31. Moghimi, S.M.; Hunter, A.C.; Murray, J.C. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev., 2001, 53, 283-318
32. Chen, L.T. Intrasplenic microcirculation in rats with acute hemolytic anemia. Blood, 1980, 56, 737-740
33. Moghimi, S.M. Prolonging the circulation time and modifying the body distribution of intravenously injected polystyrene nanospheres by prior intravenous administration of poloxamine-908. A ‘hepaticblockade’ event or manipulation of nanosphere surface in vivo? Biochim. Biophys. Acta, 1997, 1336, 1-6
34. Chen, L.T.; Weiss, L. The role of the sinus wall in the passage of erythrocytes through the spleen. Blood, 1973, 41, 529-537
35. Moghimi, S.M. Mechanisms of splenic clearance of blood cells and particles: towards development of new splenotropic agents. Adv. Drug Deliv. Rev., 1995, 17, 103-115
36. Peracchia, M.T.; Fattal, E.; Desmaele, D.; Besnard, M.; Noel, J.P.; Gomis, J.M.; Appel, M.; d’Angelo, J.; Couvreur, P. Stealth PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting. J. Control. Release Soc., 1999, 60, 121-128
37. Vaupel, P.; Kallinowski, F.; Okunieff, P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res., 1989, 49, 6449-6465
38. Ruoslahti, E. Specialization of tumour vasculature. Nat. Rev. Cancer, 2002, 2, 83-90
39. Rossin, R.; Pan, D.; Qi, K.; Turner, J.L.; Sun, X.; Wooley, K.L.; Welch, M.J. 64Cu-labeled folate-conjugated shell cross-linked nanoparticles for tumor imaging and radiotherapy: synthesis, radiolabeling, and biologic evaluation. J. Nucl. Med., 2005, 46, 1210-1218
40. Kirpotin, D.B.; Drummond, D.C.; Shao, Y.; Shalaby, M.R.; Hong, K.; Nielsen, U.B.; Marks, J.D.; Benz, C.C.; Park, J.W. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res., 2006, 66, 6732-6740
41. Zhan, C.; Gu, B.; Xie, C.; Li, J.; Liu, Y.; Lu, W. Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect. J. Control Release, 2010, 143, 136-142
42. Yadav, A.K.; Mishra, P.; Jain, S.; Mishra, P.; Mishra, A.K.; Agrawal, G.P. Preparation and characterization of HA-PEG-PCL intelligent core-corona nanoparticles for delivery of doxorubicin. J. Drug Target, 2015, 16, 464-478
43. Yadav, A.K.; Mishra, P.; Mishra, A.K.; Mishra, P.; Jain, S.; Agrawal, G.P. Development and characterization of hyaluronic acid-anchored PLGA nanoparticulate carriers of doxorubicin. Nanomedicine, 2007, 3, 246-257
44. De Jong, W.H.; Hagens, W.I.; Krystek, P.; Burger, M.C.; Sips, A.J.; Geertsma, R.E. Particle size-dependent organ distribution of gold nanoparticles after intravenous administration. Biomaterials, 2008, 29, 1912-1919
45. Deen, W. M. What determines glomerular capillary permeability? J. Clin. Invest., 2004, 114, 1412-1414
46. Haraldsson, B.; Nystrom, J.; Deen, W.M. Properties of the glomerular barrier and mechanisms of proteinuria. Physiol. Rev., 2008, 88, 451-487
47. Luboldt, W.; Pinkert, J.; Matzky, C.; Wunderlich, G.; Kotzerke, J. Radiopharmaceutical tracking of particles injected into tumors: a model to study clearance kinetics. Curr. Drug Deliv., 2009, 6, 255-260
48. Choi, H.S.; Liu, W.; Misra, P.; Tanaka, E.; Zimmer, J.P.; Itty Ipe, B.; Bawendi, M.G.; Frangioni, J.V. Renal clearance of quantum dots. Nat. Biotechnol., 2007, 25, 1165-1170
49. Nigavekar, S.S.; Sung, L.Y.; Llanes, M.; El-Jawahri, A.; Lawrence, T.S.; Becker, C.W.; Balogh, L.; Khan, M.K. H-3 dendrimer nanoparticle organ/tumor distribution. Pharm. Res., 2004, 21, 476-483
50. Wisse, E.; Braet, F.; Luo, D.; De Zanger, R.; Jans, D.; Crabbe, E.; Vermoesen, A. Structure and function of sinusoidal lining cells in the liver. Toxicol. Pathol., 1996, 24, 100-111
51. Balasubramanian, S.K.; Jittiwat, J.; Manikandan, J.; Ong, C.N.; Yu, L.E.; Ong, W.Y. Biodistribution of gold nanoparticles and gene expression changes in the liver and spleen after intravenous administration in rats. Biomaterials, 2010, 31, 2034-2042
52. Sadauskas, E.; Danscher, G.; Stoltenberg, M.; Vogel, U.; Larsen, A.; Wallin, H. Protracted elimination of gold nanoparticles from mouse liver. Nanomedicine, 2009, 5, 162-169
53. Reszka, R.; Beck, P.; Fichtner, I.; Hentschel, M.; Richter, J.; Kreuter, J. Body distribution of free, liposomal and nanoparticleassociated mitoxantrone in B16-melanoma-bearing mice. J. Pharmacol. Exp. Ther., 1997, 280, 232-237
54. Zhang, G.; Yang, Z.; Lu, W.; Zhang, R.; Huang, Q.; Tian, M.; Li, L.; Liang, D.; Li, C. Influence of anchoring ligands and particle size on the colloidal stability and in vivo biodistribution of polyethylene glycol-coated gold nanoparticles in tumorxenografted mice. Biomaterials, 2009, 30, 1928-1936
55. Moghimi, S.M.; Hedeman, H.; Muir, I.S.; Illum, L.; Davis, S.S. An investigation of the filtration capacity and the fate of large filtered sterically-stabilized microspheres in rat spleen. Biochim. Biophys. Acta, 1993, 1157, 233-240
56. Schmidt, M.M.; Wittrup, K.D. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol. Cancer Ther., 2009, 8, 2861-2871
57. Pedersen, M.B.; Zhou, X.; Larsen, E.K.; Sorensen, U.S.; Kjems, J.; Nygaard, J.V.; Nyengaard, J.R.; Meyer, R.L.; Boesen, T.; Vorup-Jensen, T. Curvature of synthetic and natural surfaces is an important target feature in classical pathway complement activation. J. Immunol., 2010, 184, 1931-1945
58. Deng, Z.J.; Liang, M.; Monteiro, M.; Toth, I.; Minchin, R.F. Nanoparticle-induced unfolding of fibrinogen promotes Mac-1 receptor activation and inflammation. Nat. Nanotechnol., 2011, 6, 39-44
59. Harashima, H.; Sakata, K.; Funato, K.; Kiwada, H. Enhanced hepatic uptake of liposomes through complement activation depending on the size of liposomes. Pharm. Res., 1994, 11, 402-406
60. Moghimi, S.M.; Hedeman, H.; Christy, N.M.; Illum, L.; Davis, S. S. Enhanced hepatic clearance of intravenously administered sterically stabilized microspheres in zymosan-stimulated rats. J. Leukoc. Biol., 1993, 54, 513-517
61. Champion, J.A.; Walker, A.; Mitragotri, S. Role of particle size in phagocytosis of polymeric microspheres. Pharm. Res., 2008, 25, 1815-1821
62. Dellian, M.; Yuan, F.; Trubetskoy, V.S.; Torchilin, V.P.; Jain, R.K. Vascular permeability in a human tumour xenograft: molecular charge dependence. Br. J. Cancer, 2000, 82, 1513-1518
63. Bartsch, M.; Weeke-Klimp, A.H.; Morselt, H.W.; Kimpfler, A.; Asgeirsdottir, S.A.; Schubert, R.; Meijer, D.K.; Scherphof, G.L.; Kamps, J.A. Optimized targeting of polyethylene glycol-stabilized anti-intercellular adhesion molecule 1 oligonucleotide/lipid particles to liver sinusoidal endothelial cells. Mol. Pharmacol., 2005, 67, 883-890
64. Lundqvist, M.; Stigler, J.; Elia, G.; Lynch, I.; Cedervall, T.; Dawson, K.A. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc. Natl. Acad. Sci. U.S.A., 2008, 105, 14265-14270
65. Decuzzi, P.; Pasqualini, R.; Arap, W.; Ferrari, M. Intravascular delivery of particulate systems: does geometry really matter? Pharm. Res., 2009, 26, 235-243
66. Champion, J.A.; Mitragotri, S. Role of target geometry in phagocytosis. Proc. Natl. Acad. Sci. U.S.A., 2006, 103, 4930-4934
67. Geng, Y.; Dalhaimer, P.; Cai, S.; Tsai, R.; Tewari, M.; Minko, T.; Discher, D.E. Shape effects of filaments versus spherical particles in flow and drug delivery. Nat. Nanotechnol., 2007, 2, 249-255
68. Arnida Janat-Amsbury, M.M.; Ray, A.; Peterson, C.M.; Ghandehari, H. Geometry and surface characteristics of gold nanoparticles influence their biodistribution and uptake by macrophages. Eur. J. Pharm. Biopharm., 2011, 77, 417-423
69. Zhu, S.; Hong, M.; Tang, G.; Qian, L.; Lin, J.; Jiang, Y.; Pei, Y. Partly PEGylated polyamidoamine dendrimer for tumor-selective targeting of doxorubicin: the effects of PEGylation degree and drug conjugation style. Biomaterials, 2010, 31, 1360-1371
70. Medina, S.H.; Tiruchinapally, G.; Chevliakov, M.V.; Durmaz, Y.Y.; Stender, R.N.; Ensminger, W.D.; Shewach, D.S.; Elsayed, M.E. Targeting hepatic cancer cells with pegylated dendrimers displaying N-acetylgalactosamine and SP94 peptide ligands. Adv. Healthc Mater., 2013, 2, 1337-1350
71. Drummond, D.C.; Meyer, O.; Hong, K.; Kirpotin, D.B.; Papahadjopoulos, D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol. Rev., 1999, 51, 691-743
72. Li, F.; Pincet, F. Confinement free energy of surfaces bearing endgrafted, polymers in the mushroom regime and local measurement of the polymer density. Langmuir, 2007, 23, 12541-12548
73. Dufort, S.; Sancey, L.; Coll, J.L. Physico-chemical parameters that govern nanoparticles fate also dictate rules for their molecular evolution. Adv. Drug Deliv. Rev., 2012, 64, 179-189
74. Kumar, P.V.; Lokesh, B.V.S. Designing and In-Vitro Characterization of Micelle Forming Amphiphilic PEGylated Rapamycin Nanocarriers for the Treatment of Gastric Cancer. Curr. Drug Deliv., 2014, 11, 613-620
75. Storm, G.; Belliot, S.O.; Daemen, T.; Lasic, D.D. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv. Drug Deliv. Rev., 1995, 17, 31-48
76. Tirosh, O.; Barenholz, Y.; Katzhendler, J.; Priev, A. Hydration of polyethylene glycol-grafted liposomes. Biophys. J., 1998, 74, 1371-1379
77. Cavadas, M.; Gonzalez-Fernandez, A.; Franco, R. Pathogenmimetic stealth nanocarriers for drug delivery: a future possibility. Nanomedicine, 2011, 7, 730-743
78. Ishida, T.; Kashima, S.; Kiwada, H. The contribution of phagocytic activity of liver macrophages to the accelerated blood clearance (ABC) phenomenon of PEGylated liposomes in rats. J. Control Release, 2008, 126, 162-165
79. Alvarez, A.I.; Merino, G.; Molina, A.J.; Pulido, M.M.; McKellar, Q.A.; Prieto, J.G. Role of ABC transporters in veterinary drug research and parasite resistance. Curr. Drug Deliv., 2006, 3, 199-206
80. Romberg, B.; Hennink, W.E.; Storm, G. Sheddable coatings for long-circulating nanoparticles. Pharm. Res., 2008, 25, 55-71
81. Ai, X.; Sun, J.; Zhong, L.; Wu, C.; Niu, H.; Xu, T.; Lian, H.; Han, X.; Ren, G.; Ding, W.; Wang, J.; Pu, X.; He, Z. Star-shape redoxresponsive PEG-sheddable copolymer of disulfide-linked polyethylene glycol-lysine-di-tocopherol succinate for tumortriggering intracellular doxorubicin rapid release: head-to-head comparison. Macromol. Biosci., 2014, 14, 1415-1428
82. Ruoslahti, E.; Bhatia, S.N.; Sailor, M.J. Targeting of drugs and nanoparticles to tumors. J. Cell Biol., 2010, 188, 759-768
83. Sapra, P.; Tyagi, P.; Allen, T.M. Ligand-targeted liposomes for cancer treatment. Curr. Drug Deliv., 2005, 2, 369-381
84. Danhier, F.; Feron, O.; Preat, V. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J. Control Release, 2010, 148, 135-146
85. Bartlett, D.W.; Su, H.; Hildebrandt, I.J.; Weber, W.A.; Davis, M.E. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc. Natl. Acad. Sci. U.S.A., 2007, 104, 15549-15554
86. Singh, A.; Dilnawaz, F.; Sahoo, S.K. Long circulating lectin conjugated paclitaxel loaded magnetic nanoparticles: a new theranostic avenue for leukemia therapy. PLoS One, 2011, 6, e26803
87. Mamot, C.; Drummond, D.C.; Greiser, U.; Hong, K.; Kirpotin, D.B.; Marks, J.D.; Park, J.W. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFRand EGFRvIII-overexpressing tumor cells. Cancer Res., 2003, 63, 3154-3161
88. Pirollo, K.F.; Chang, E.H. Does a targeting ligand influence nanoparticle tumor localization or uptake? Trends Biotechnol., 2008, 26, 552-558
89. Torchilin, V. P. Lipid-core micelles for targeted drug delivery. Curr. Drug Deliv., 2005, 2, 319-327
90. Ferrara, N. VEGF as a therapeutic target in cancer. Oncology, 2005, 69 Suppl 3, 11-16
91. Yu, D.H.; Lu, Q.; Xie, J.; Fang, C.; Chen, H.Z. Peptide-conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neovasculature. Biomaterials, 2010, 31, 2278-2292
92. Sugahara, K.N.; Teesalu, T.; Karmali, P.P.; Kotamraju, V.R.; Agemy, L.; Girard, O.M.; Hanahan, D.; Mattrey, R.F.; Ruoslahti, E. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell, 2009, 16, 510-520
93. Sugahara, K.N.; Teesalu, T.; Karmali, P.P.; Kotamraju, V.R.; Agemy, L.; Greenwald, D.R.; Ruoslahti, E. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science, 2010, 328, 1031-1035
94. Maruyama, K.; Kennel, S.J.; Huang, L. Lipid composition is important for highly efficient target binding and retention of immunoliposomes. Proc. Natl. Acad. Sci. U.S.A., 1990, 87, 5744-5748
95. Allen, T.M. Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends Pharmacol. Sci., 1994, 15, 215-220
96. Tortorella, S.; Karagiannis, T.C. The Significance of Transferrin Receptors in Oncology: the Development of Functional Nanobased Drug Delivery Systems. Curr. Drug Deliv., 2014, 11, 427-443
97. Perry, J.L.; Herlihy, K.P.; Napier, M.E.; Desimone, J.M. PRINT: A Novel Platform Toward Shape and Size Specific Nanoparticle Theranostics. Acc. Chem. Res., 2011, 44, 990-998
98. Merian, J.; De Souza, R.; Dou, Y.; Ekdawi, S.N.; Ravenelle, F.; Allen, C. Development of a liposome formulation for improved biodistribution and tumor accumulation of pentamidine for oncology applications. Int. J. Pharm., 2015, 488, 154-164
99. Jain, V.; Jain, S.; Mahajan, S.C. Nanomedicines Based Drug Delivery Systems for Anti-Cancer Targeting and Treatment. Curr. Drug Deliv., 2015, 12, 177-191
100. Euliss, L.E.; DuPont, J.A.; Gratton, S.; DeSimone, J. Imparting size, shape, and composition control of materials for nanomedicine. Chem. Soc. Rev., 2006, 35, 1095-1104
101. Ochekpe, N.A.; Olorunfemi, P.O.; Ngwuluka, N.C. Nanotechnology and Drug Delivery Part 2: Nanostructures for Drug Delivery. Trop. J. Pharm. Res., 2009, 8, 275-287
102. Soman, C.; Giorgio, T. Kinetics of molecular recognition mediated nanoparticle self-assembly. Nano Res., 2010, 2, 78-84
103. Canelas, D.A.; Herlihy, K.P.; DeSimone, J.M. Top-down particle fabrication: control of size and shape for diagnostic imaging and drug delivery. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 2009, 1, 391-404
104. Glangchai, L.C.; Caldorera-Moore, M.; Shi, L.; Roy, K. Nanoimprint lithography based fabrication of shape-specific, enzymatically-triggered smart nanoparticles. J. Control Release, 2008, 125, 263-272
105. Gratton, S.E.A.; Pohhau S. P.D.; Lee, J.; Guo, I.; Cho, M.J.; DeSimone, J.M. Nanofabricated particles for engineered drug therapies: A preliminary Biodistribution study of PRINT (TM) nanoparticles. J. Control Release, 2007, 121, 10-18
106. Wang, J.; Tian, S.; Petros, R.A.; Napier, M.E.; Desimone, J.M. The complex role of multivalency in nanoparticles targeting the transferrin receptor for cancer therapies. J. Am. Chem. Soc., 2010, 132, 11306-11313
107. Petros, R.A.; Ropp, P.A.; DeSimone, J.M. Reductively labile PRINT particles for the delivery of doxorubicin to HeLa cells. J. Am. Chem. Soc., 2008, 130, 5008-5009
108. Kelly, J.Y.; DeSimone, J.M. Shape-specific, monodisperse nanomolding of protein particles. J. Am. Chem. Soc., 2008, 130, 5438-5439
109. Yoo, J.W.; Doshi, N.; Mitragotri, S. Adaptive micro and nanoparticles: temporal control over carrier properties to facilitate drug delivery. Adv. Drug Deliv. Rev., 2011, 63, 1247-1256
110. Ibsen, S.; Benchimol, M.; Simberg, D.; Schutt, C.; Steiner, J.; Esener, S. A novel nested liposome drug delivery vehicle capable of ultrasound triggered release of its payload. J. Control Release, 2011, 155, 358-366
111. Danquah, M.K.; Zhang, X.A.; Mahato, R.I. Extravasation of polymeric nanomedicines across tumor vasculature. Adv. Drug Deliv. Rev., 2011, 63, 623-639
112. Fang, J.; Nakamura, H.; Maeda, H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Deliv. Rev., 2011, 63, 136-151
113. Znati, C.A.; Rosenstein, M.; Boucher, Y.; Epperly, M.W.; Bloomer, W.D.; Jain, R.K. Effect of radiation on interstitial fluid pressure and oxygenation in a human tumor xenograft. Cancer Res., 1996, 56, 964-968
114. Li, C.; Ke, S.; Wu, Q.P.; Tansey, W.; Hunter, N.; Buchmiller, L.M.; Milas, L.; Charnsangavej, C.; Wallace, S. Tumor irradiation enhances the tumor-specific distribution of poly(L-glutamic acid)conjugated paclitaxel and its antitumor efficacy. Clin. Cancer Res., 2000, 6, 2829-2834
115. Kong, G.; Braun, R.D.; Dewhirst, M.W. Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size. Cancer Res., 2000, 60, 4440-4445
116. Hauck, M.L.; Dewhirst, M.W.; Bigner, D.D.; Zalutsky, M.R. Local hyperthermia improves uptake of a chimeric monoclonal antibody in a subcutaneous xenograft model. Clin. Cancer Res., 1997, 3, 63-70
117. Kong, G.; Braun, R.D.; Dewhirst, M.W. Characterization of the effect of hyperthermia on nanoparticle extravasation from tumor vasculature. Cancer Res., 2001, 61, 3027-3032
118. Ryu, J.S.; Raucher, D. Elastin-like polypeptides: the influence of its molecular weight on local hyperthermia-induced tumor accumulation. Eur. J. Pharm. Biopharm., 2014, 88, 382-389
119. Zhang, L.; Yu, F.; Cole, A.J.; Chertok, B.; David, A.E.; Wang, J.; Yang, V.C. Gum arabic-coated magnetic nanoparticles for potential application in simultaneous magnetic targeting and tumor imaging. AAPS J., 2009, 11, 693-699
120. Chertok, B.; Moffat, B.A.; David, A.E.; Yu, F.; Bergemann, C.; Ross, B.D.; Yang, V.C. Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors. Biomaterials, 2008, 29, 487-496
121. Che, E.; Wan, L.; Zhang, Y.; Zhao, Q.; Han, X.; Li, J.; Liu, J.; Wang, S. Development of phosphonate-terminated magnetic mesoporous silica nanoparticles for pH-controlled release of doxorubicin and improved tumor accumulation. Asian J. Pharm. Sci., 2014, 9, 317-323
122. Mo, S.; Coussios, C.C.; Seymour, L.; Carlisle, R. Ultrasoundenhanced drug delivery for cancer. Expert Opin. Drug Deliv., 2012, 9, 1525-1538
123. Carlisle, R.; Choi, J.; Bazan-Peregrino, M.; Laga, R.; Subr, V.; Kostka, L.; Ulbrich, K.; Coussios, C. C.; Seymour, L. W. Enhanced tumor uptake and penetration of virotherapy using polymer stealthing and focused ultrasound. J. Natl. Cancer Inst., 2013, 105, 1701-1710
124. Bazan-Peregrino, M.; Rifai, B.; Carlisle, R.C.; Choi, J.; Arvanitis, C.D.; Seymour, L.W.; Coussios, C.C. Cavitation-enhanced delivery of a replicating oncolytic adenovirus to tumors using focused ultrasound. J. Control. Release, 2013, 169, 40-47
125. Mo, S.; Carlisle, R.; Laga, R.; Myers, R.; Graham, S.; Cawood, R.; Ulbrich, K.; Seymour, L.; Coussios, C.C. Increasing the density of nanomedicines improves their ultrasound-mediated delivery to tumours. J. Control. Release, 2015, 210, 10-18
126. Bhowmik, T.; Saha, P.P.; DasGupta, A.K.; Gomes, A. Influence of Gold Nanoparticle Tagged Snake Venom Protein Toxin NKCT1 on Ehrlich Ascites Carcinoma (EAC) and EAC Induced Solid Tumor Bearing Male Albino Mice. Curr. Drug Deliv., 2014, 11, 652-664
127. Marcucci, F.; Corti, A. How to improve exposure of tumor cells to drugs: promoter drugs increase tumor uptake and penetration of effector drugs. Adv. Drug Deliv. Rev., 2012, 64, 53-68
128. Nagamitsu, A.; Greish, K.; Maeda, H. Elevating blood pressure as a strategy to increase tumor-targeted delivery of macromolecular drug SMANCS: cases of advanced solid tumors. Jpn. J. Clin. Oncol., 2009, 39, 756-766
129. Padera, T.P.; Stoll, B.R.; Tooredman, J.B.; Capen, D.; di Tomaso, E.; Jain, R.K. Cancer cells compress intratumour vessels. Nature, 2004, 427, 695-695
130. Qiao, Y.; Huang, X.; Nimmagadda, S.; Bai, R.; Staedtke, V.; Foss, C.A.; Cheong, I.; Holdhoff, M.; Kato, Y.; Pomper, M.G.; Riggins, G.J.; Kinzler, K.W.; Diaz, L.A., Jr.; Vogelstein, B.; Zhou, S. A Robust Approach to Enhance Tumor-selective Accumulation of Nanoparticles. Oncotarget, 2011, 2, 59-68
131. Ferrari, M. Frontiers in cancer nanomedicine: directing mass transport through biological barriers. Trends Biotechnol., 2010, 28, 181-188
132. Kafshgari, M.H.; Harding, F.J.; Voelcker, N.H. Insights into Cellular Uptake of Nanoparticles. Curr. Drug Deliv., 2015, 12, 63-77
133. Wong, C.; Stylianopoulos, T.; Cui, J.; Martin, J.; Chauhan, V.P.; Jiang, W.; Popovic, Z.; Jain, R.K.; Bawendi, M.G.; Fukumura, D. Multistage nanoparticle delivery system for deep penetration into tumor tissue. Proc. Natl. Acad. Sci. U.S.A., 2011, 108, 2426-2431
134. Tanaka, T.; Mangala, L.S.; Vivas-Mejia, P.E.; Nieves-Alicea, R.; Mann, A.P.; Mora, E.; Han, H.D.; Shahzad, M.M.; Liu, X.; Bhavane, R.; Gu, J.; Fakhoury, J.R.; Chiappini, C.; Lu, C.; Matsuo, K.; Godin, B.; Stone, R.L.; Nick, A.M.; Lopez-Berestein, G.; Sood, A.K.; Ferrari, M. Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res., 2010, 70, 3687-3696
135. Zdrojewicz, Z.; Waracki, M.; Bugaj, B.; Pypno, D.; Cabala, K. Medical applications of nanotechnology. Postep. Hig. Med. Dosw., 2015, 69, 1196-1204
136. Peng, Q.; Zhang, S.; Yang, Q.; Zhang, T.; Wei, X.Q.; Jiang, L.; Zhang, C.L.; Chen, Q.M.; Zhang, Z.R.; Lin, Y.F. Preformed albumin corona, a protective coating for nanoparticles based drug delivery system. Biomaterials, 2013, 34, 8521-8530
137. Wang, S.; Huang, P.; Nie, L.; Xing, R.; Liu, D.; Wang, Z.; Lin, J.; Chen, S.; Niu, G.; Lu, G.; Chen, X. Single continuous wave laser induced photodynamic/plasmonic photothermal therapy using photosensitizer-functionalized gold nanostars. Adv. Mater., 2013, 25, 3055-3061